Work

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

Year: 2018

Type: article

Abstract: We report a woman who developed BIA-ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA-ALCL.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.1382

Authors: Juan Pablo Alderuccio, Amrita Desai, Monica M. Yepes, Jennifer R. Chapman, Francisco Vega, Izidore S. Lossos

Institutions: University of Miami, Sylvester Comprehensive Cancer Center

Language: English

Topic: Breast Implant and Reconstruction

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820